Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

PR NewswireDec 23 21:01

Express News | PAVmed Inc: Files for Mixed Shelf Offering of up to $125 Mln

BreakingsDec 21 06:17

Lucid Diagnostics Partners With VITALExam, To Enhance Access To Lucid's EsoGuard Esophageal DNA Test For Firefighters At Risk For Esophageal Precancer

BenzingaDec 19 21:17

Express News | Prospective Clinical Utility Study of Lucid Diagnostics' Esoguard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

BreakingsDec 11 21:01

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication

PR NewswireDec 11 21:01

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow JonesDec 9 17:35 · Ratings